DDInter406 DDInter927
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid].
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Clofazimine {u} (Compound) binds {v} (Gene) ABCB1
Clofazimine {u} (Compound) upregulates {v} (Gene) HERPUD1
Clofazimine {u} (Compound) downregulates {v} (Gene) TUBB6
Clofazimine {u} (Compound) causes {v} (Side Effect) Dermatitis
Clofazimine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clofazimine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Clofazimine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Clofazimine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Clofazimine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Clofazimine (Compound) binds ABCB1 (Gene)
Clofazimine (Compound) upregulates HERPUD1 (Gene)
Clofazimine (Compound) downregulates TUBB6 (Gene)
Clofazimine (Compound) causes Dermatitis (Side Effect)
Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Clofazimine may lead to a major life threatening interaction when taken with Toremifene
Clofazimine may lead to a major life threatening interaction when taken with Crizotinib